Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion offer for biotech firm Metsera to deliberately stall the entry of Metsera’s next-generation obesity treatments into the market rather than to complete a legitimate acquisition.

Both Novo Nordisk and Metsera rejected Pfizer’s allegations, calling them baseless, as the high-stakes legal battle for control of the fast-growing obesity drug developer intensified. A judge is set to review the complaints on Tuesday.

Pfizer had agreed in September to pay up to $7.3 billion for Metsera after a months-long private bidding war with Novo. The dispute underscores the fierce competition among global pharmaceutical giants seeking to expand their presence in the lucrative obesity drug market, currently dominated by Novo’s blockbuster Wegovy and Ozempic treatments.